Close
Close
Finance News

Strongbridge Biopharma plc Added to the NASDAQ Biotech Index

2.8
2.8 from 5 votes
Friday, December 15, 2017

DUBLIN, Ireland and TREVOSE, Pa. - Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq:NBI), which will become effective prior to market open on Monday, December 18, 2017.

The NASDAQ Biotechnology Index is a modified market capitalization weighted index that is designed to track the performance of a set of securities listed on The NASDAQ Stock Market, that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark and is re-ranked annually in December. The NASDAQ Biotechnology Index is the basis for the iShares NASDAQ Biotechnology Index Fund (Nasdaq:IBB), which seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the NASDAQ Biotechnology Index. In addition, options based on the iShares NASDAQ Biotechnology Index Fund trade on various exchanges. For more information about the NASDAQ Biotechnology Index please visit https://indexes.nasdaqomx.com/Index/Overview/NBI.

About Strongbridge Biopharma
Strongbridge Biopharma is a commercial-stage global biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge's first commercial product is KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis. KEVEYIS has orphan drug exclusivity status in the U.S. through August 7, 2022. In addition to establishing this neuromuscular disease franchise, the Company has a clinical-stage pipeline of therapies for rare endocrine diseases. Strongbridge's lead compounds include RECORLEV™ (levoketoconazole), a cortisol synthesis inhibitor currently being studied for the treatment of endogenous Cushing's syndrome, and veldoreotide, a next-generation somatostatin analog being investigated for the treatment of acromegaly, with potential additional applications in Cushing's syndrome and neuroendocrine tumors. Both RECORLEV and veldoreotide have received orphan designation from the U.S. Food and Drug Administration and the European Medicines Agency. For more information, visit www.strongbridgebio.com.

Contacts:

Corporate and Media Relations
Elixir Health Public Relations
Lindsay Rocco
Phone: +1 862-596-1304
Email: lrocco@elixirhealthpr.com

Investor Relations
U.S.:
The Trout Group
Marcy Nanus
Phone: +1 646-378-2927
Email: mnanus@troutgroup.com

Europe:
First House
Mitra Hagen Negård
Phone: +47 21 04 62 19
Email: strongbridgebio@firsthouse.no

USA
900 Northbrook Drive
Suite 200
Trevose, PA 19053
Phone: +1 610-254-9200
Fax. +1 215-355-7389

Source: Strongbridge Biopharma plc
2.8
2.8 from 5 votes
Free Newsletter
Trending News
Videos
by Abidemi Uruejoma
14 views
by Abidemi Uruejoma
33 views
by Abidemi Uruejoma
51 views